$APRE
Aprea Therapeutics, Inc. Common stock
XNAS•Health Care•Pharmaceutical Preparations
$0.733
▲+0.29%+$0.002
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateAprea Therapeutics, Inc. Common stock
XNAS•Health Care•Pharmaceutical Preparations
Why is APRE up today? It is at $0.733 (+0.29%), and our scanner flagged it 48 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment APRE spikes, and full due diligence on APRE — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $APRE 48 times in the last 30 days. Create a free account to track $APRE, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on APRE from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for APRE today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Seizinger Bernd R. Director | Acquired (grant/award) | +3K 0.02% of company | added 6.8% | 49K | n/a | Jun 16, 26 |
Pamukcu Rifat Director | Acquired (grant/award) | +3K 0.02% of company | added 58% | 9K | n/a | Jun 16, 26 |
Duey Marc Director | Acquired (grant/award) | +3K 0.02% of company | added 1.2% | 259K | n/a | Jun 16, 26 |
Bizzari Jean-Pierre Director | Acquired (grant/award) | +3K 0.02% of company | added 100% | 4K | n/a | Jun 16, 26 |
Henneman John B Iii Director | Acquired (grant/award) | +3K 0.02% of company | added 31% | 13K | n/a | Jun 16, 26 |
Peters Richard Director | Acquired (grant/award) | +3K 0.02% of company | added 100% | 6K | n/a | Jun 16, 26 |
Gruia Gabriela Director | Acquired (grant/award) | +3K 0.02% of company | added 100% | 4K | n/a | Jun 16, 26 |
Grissinger Michael Director | Acquired (grant/award) | +3K 0.02% of company | added 100% | 6K | n/a | Jun 16, 26 |
Hamill John P. Officer | Acquired (grant/award) | +10K 0.08% of company | added 30% | 44K | n/a | Mar 12, 26 |
Gilad Oren Officer | Acquired (grant/award) | +20K 0.2% of company | added 5.4% | 394K | n/a | Mar 12, 26 |
Hamill John P. Officer | Bought (open market) | +6K 0.05% of company | added 21% | 33K | $5K at $0.890 | Jan 30, 26 |
Gilad Oren Officer | Bought (open market) | +28K 0.2% of company | added 8.1% | 374K | $25K at $0.890 | Jan 30, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on APRE from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for APRE today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
APRE last traded at $0.733, up 0.29% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Aprea Therapeutics, Inc. Common stock (APRE) is next expected to report earnings on Wednesday, November 11, 2026, about 55 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The APRE Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged APRE 48 times in the last 30 days.
APRE (Aprea Therapeutics, Inc. Common stock) trades on XNAS, with a market cap of about $9M in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge APRE for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$APRE discussion
Sign in to ask a question or join the discussion.